⏱ News is delayed by 15 minutes. Sign in for real-time access.
Sign in
RARE News
Ultragenyx Pharmaceutical Inc.
Ultragenyx Pharmaceutical Inc. Notice of April 6, 2026 Application Deadline for Class Action Lawsuit - Contact Lewis Kahn, Esq. at Kahn Swick & Foti, LLC, Before Application Deadline
accessnewswire.com
RARE
ROSEN, A TOP RANKED LAW FIRM, Encourages Ultragenyx Pharmaceutical Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action - RARE
accessnewswire.com
RARE
Pomerantz LLP Issues Important Reminder to Investors in Ultragenyx Pharmaceutical Inc. of Class Action Filing – RARE
accessnewswire.com
RARE
Levi & Korsinsky, LLP: April 6, 2026 --- Deadline to Seek Lead Plaintiff Role in Ultragenyx Pharmaceutical Securities Class Action
globenewswire.com
RARE
RARE INVESTOR DEADLINE APPROACHING: Faruqi & Faruqi, LLP Reminds Ultragenyx Pharmaceutical (RARE) Investors of Securities Class Action Deadline on April 6, 2026
prnewswire.com
RARE
Portnoy Law Firm Announces Class Action on Behalf of Ultragenyx Pharmaceutical, Inc. Investors
globenewswire.com
RARE
RARE Investors Have Opportunity to Lead Ultragenyx Pharmaceutical Inc. Securities Fraud Lawsuit with the Schall Law Firm
globenewswire.com
RARE
RARE Investors Have Opportunity to Lead Ultragenyx Pharmaceutical Inc. Securities Fraud Lawsuit with the Schall Law Firm
globenewswire.com
RARE
Amlogenyx Announces Positive Preclinical Data on AM805, a Potent Amyloid-Degrading Protease for the Treatment of Alzheimer’s Disease
globenewswire.com
RARE
Amlogenyx Announces Positive Preclinical Data on AM805, a Potent Amyloid-Degrading Protease for the Treatment of Alzheimer’s Disease
globenewswire.com
RARE